author-photo

Harald Zeuner

Hoffmann-La Roche

7

Papers

170

Citations

Citation Trend

Filter By

Papers (6) Sort By

Journal Conference Others

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (81)
Obinutuzumab-Based Immunochemotherapy Prolongs Progression-Free Survival and Time to Next Anti-Lymphoma Treatment in Patients with Previously Untreated Follicular Lymphoma: Four-Year Results from the Phase III GALLIUM Study

2018 Blood
Show All
- Source
- Cite
- Save
Citations (9)
Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study

2018 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Long Term Follow-up of the PRIMA Study: Half of Patients Receiving Rituximab Maintenance Remain Progression Free at 10 Years

2017 Blood
Show All
- Source
- Cite
- Save
Citations (38)
Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials

2017 Blood
Show All
- Source
- Cite
- Save
Citations (2)
IMMUNOCHEMOTHERAPY WITH OBINUTUZUMAB OR RITUXIMAB IN a SUBSET OF PATIENTS IN THE RANDOMISED GALLIUM TRIAL WITH PREVIOUSLY UNTREATED MARGINAL ZONE LYMPHOMA (MZL)

2017 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (10)